Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04016740 · ClinicalTrials.gov registry record · Early Phase 1
The PATHFINDER Study: A Feasibility Trial
A Early Phase 1 study, sponsored by Beth Israel Deaconess Medical Center.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 22
- Enrollment target
NCT04016740 is a Early Phase 1 study that has completed, run by Beth Israel Deaconess Medical Center. The registered enrollment target is 22 participants.
The verdict
NCT04016740, a Early Phase 1 study, has completed, sponsored by Beth Israel Deaconess Medical Center.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 22 participants
- Enrollment target
Study Summary
The main purpose of this study is to determine whether a rational strategy of EEG guided multimodal general anesthesia using target specific sedative and analgesics could result in enhanced recovery after anesthesia and surgery, decrease in postoperative delirium, and decrease in long term postoperative cognitive dysfunction up to 6 months following cardiac surgery.
Interventions
- DRUG Ketamine
- DRUG Rocuronium
- DRUG Dexmedetomidine
- DRUG Ropivacaine
- DRUG Remifentanil
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2019-08-20 |
| Est. Completion | 2020-07-07 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04016740
The ClinicalTrials.gov registry entry for NCT04016740 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Beth Israel Deaconess Medical Center, which has 488 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Ketamine is the first listed.
NCT04016740 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04016740 about?
NCT04016740 is a clinical study titled "The PATHFINDER Study: A Feasibility Trial". The main purpose of this study is to determine whether a rational strategy of EEG guided multimodal general anesthesia using target specific sedative and analgesics could result in enhanced recovery after anesthesia and surgery, decrease in postoperative delirium, and decrease in long term postopera...
What is the current status of trial NCT04016740?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 22 participants. The study started on 2019-08-20. Estimated completion is 2020-07-07.
What interventions are being tested in trial NCT04016740?
The interventions under investigation include: Ketamine (DRUG), Rocuronium (DRUG), Dexmedetomidine (DRUG), Ropivacaine (DRUG), Remifentanil (DRUG).
Who is sponsoring clinical trial NCT04016740?
This trial is sponsored by Beth Israel Deaconess Medical Center, which has 488 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.